Hill Tanner K, Kelkar Sneha S, Wojtynek Nicholas E, Souchek Joshua J, Payne William M, Stumpf Kristina, Marini Frank C, Mohs Aaron M
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Department of Plastic and Reconstructive Surgery, Wake Forest University Health Sciences, Winston-Salem, NC 27157, United States.
Theranostics. 2016 Oct 1;6(13):2314-2328. doi: 10.7150/thno.16514. eCollection 2016.
Tumor tissue that remains undetected at the primary surgical site can cause tumor recurrence, repeat surgery, and treatment strategy alterations that impose a significant patient and healthcare burden. Intraoperative near infrared fluorescence (NIRF) imaging is one potential method to identify remaining tumor by visualization of NIR fluorophores that are preferentially localized to the tumor. This requires development of fluorophores that consistently identify tumor tissue in different patients and tumor types. In this study we examined a panel of NIRF contrast agents consisting of polymeric nanoparticle (NP) formulations derived from hyaluronic acid (HA), with either physically entrapped indocyanine green (ICG) or covalently conjugated Cy7.5. Using orthotopic human breast cancer MDA-MB-231 xenografts in nude mice we identified two lead formulations. One, NanoICG, with physicochemically entrapped ICG, showed 2.3-fold greater tumor contrast than ICG alone at 24 h (p < 0.01), and another, NanoCy7.5, with covalently conjugated Cy7.5, showed 74-fold greater tumor contrast than Cy7.5 alone at 24 h (p < 0.0001). These two lead formulations were then tested in immune competent BALB/c mice bearing orthotopic 4T1 breast cancer tumors. NanoICG showed 2.2-fold greater contrast than ICG alone (p < 0.0001), and NanoCy7.5 showed 14.8-fold greater contrast than Cy7.5 alone (p < 0.0001). Furthermore, both NanoICG and NanoCy7.5 provided strong tumor enhancement using image-guided surgery in mice bearing 4T1 tumors. These studies demonstrate the efficacy of a panel of HA-derived NPs in delineating tumors , and identifies promising formulations that can be used for future tumor removal efficacy studies.
在初次手术部位未被检测到的肿瘤组织可导致肿瘤复发、再次手术以及治疗策略改变,给患者和医疗保健带来沉重负担。术中近红外荧光(NIRF)成像通过可视化优先定位于肿瘤的NIR荧光团来识别残留肿瘤,是一种潜在的方法。这需要开发能够在不同患者和肿瘤类型中持续识别肿瘤组织的荧光团。在本研究中,我们检测了一组NIRF造影剂,这些造影剂由源自透明质酸(HA)的聚合物纳米颗粒(NP)制剂组成,其中物理包裹了吲哚菁绿(ICG)或共价偶联了Cy7.5。使用人乳腺癌MDA-MB-231原位异种移植裸鼠模型,我们确定了两种领先制剂。一种是物理包裹ICG的NanoICG,在24小时时肿瘤对比度比单独使用ICG高2.3倍(p < 0.01);另一种是共价偶联Cy7.5的NanoCy7.5,在24小时时肿瘤对比度比单独使用Cy7.5高74倍(p < 0.0001)。然后在携带原位4T1乳腺癌肿瘤的免疫活性BALB/c小鼠中测试这两种领先制剂。NanoICG的对比度比单独使用ICG高2.2倍(p < 0.0001),NanoCy7.5的对比度比单独使用Cy7.5高14.8倍(p < 0.0001)。此外,在携带4T1肿瘤的小鼠中,NanoICG和NanoCy7.5通过图像引导手术均提供了强烈的肿瘤增强效果。这些研究证明了一组源自HA的NP在描绘肿瘤方面的有效性,并确定了可用于未来肿瘤切除疗效研究的有前景的制剂。